BioMidwest
Filter News
Found 77,790 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System
2/3/2023
SPR Therapeutics announced it has obtained clearance from the U.S. Food and Drug Administration (FDA) for expanded labeling, which increases the intended patient population of the SPRINT® PNS System, along with new advances to enhance and simplify the SPRINT PNS System’s lead securement mechanism.
-
Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer
2/3/2023
Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead all business development, partnering and growth strategies for Predictive Oncology.
-
Zimmer Biomet Announces Fourth Quarter and Full-Year 2022 Financial Results
2/3/2023
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2022.
-
ROSALIND FRANKLIN UNIVERSITY STARTUP PREPARING FOR FDA IND FILING AND A PIVOTAL CLINICAL TRIAL ON NOVEL THERAPY FOR SUDDEN CARDIAC ARREST
2/2/2023
Rosalind Franklin University of Medicine and Science (RFU) announced today that one of its early-stage companies — Resuscitation Therapeutics (RTx), which is focused on developing new therapies for life-threatening acute cardiovascular events — is preparing an Investigational New Drug (IND) application for submission to the U.S. Food and Drug Administration proposing a novel treatment for sudden cardiac arrest (SCA).
-
Rockwell Medical Signs Three-Year, Multi-Million Dollar Supply Agreement with Largest Non-Profit Dialysis Provider in the United States
2/2/2023
Rockwell Medical, Inc. announced that the Company signed a three-year, multi-million dollar per annum product purchase agreement with the largest non-profit dialysis provider in the United States.
-
Cardinal Health Reports Second Quarter Fiscal Year 2023 Results and Raises Fiscal Year 2023 Non-GAAP EPS Guidance
2/2/2023
Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2023 revenues of $51.5 billion, an increase of 13% from the second quarter of fiscal year 2022.
-
Medline and MDHearing partner to offer consumers over-the-counter hearing aids
2/2/2023
Medline announced a new partnership with MDHearing, a direct-to-consumer hearing aid manufacturer, to make it easier for people to purchase affordable hearing aids without a prescription.
-
POINT Biopharma to Participate in Upcoming Investor Conferences - February 02, 2023
2/2/2023
POINT Biopharma Global Inc., a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, announced management will participate in the following upcoming investor conferences.
-
BioLife Sciences Inc. (OTC: BLFE) Announces Letter of Intent for Exclusive Licensing Deal with Canadian Firm
2/2/2023
BioLife Sciences is pleased to announce that it has entered into a non-binding letter of intent dated February 01, 2023 with Canadian Company–Work In Motion pursuant to which the parties will complete an exclusive licensing agreement for the development and commercialization of custom designed copper infused bamboo gardening gloves.
-
My Cardiologist Launches The Women's Heart Health Program
2/2/2023
Novocardia, a value-based cardiovascular disease care platform, and My Cardiologist, a trusted provider of cardiovascular services in South Florida for more than 60 years, are pleased to announce the launch of The Women's Heart Health Program in South Florida.
-
Bio-Techne Releases Second Quarter Fiscal 2023 Results
2/2/2023
Bio-Techne Corporation reported its financial results for the second quarter ended December 31, 2022.
-
The Center for Global Health Innovation Selects Former American Cancer Society CEO, Gary M. Reedy, as Chairman of their Board
2/2/2023
The Center for Global Health Innovation announced that Gary M. Reedy will be their new chairman.
-
Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida
2/2/2023
Vaxxinity, Inc., a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced new appointments to the Board of Directors and the relocation of its corporate headquarters to Cape Canaveral, Fla.
-
Gravity Diagnostics Receives Accreditation From the College of American Pathologists
2/2/2023
The Accreditation Committee of the College of American Pathologists has awarded accreditation to Gravity Diagnostics based on the results of a recent on-site inspection as part of the CAP’s Accreditation Programs.
-
Athersys to Host Business Update Conference Call on February 14th
2/2/2023
Athersys, Inc. (NASDAQ: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today it will host a business update conference call on February 14, 2023 at 11:00 a.m. Eastern Time.
-
ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference
2/2/2023
ONL Therapeutics, Inc. announced today that David Esposito, chief executive officer, will present a corporate update at the BIO CEO & Investor Conference on Monday, February 6, 2023, at 2:00 p.m. ET.
-
Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023
2/2/2023
Xeris Biopharma, Inc. today announced that members of its senior management will hold 1x1 investor meetings and present an overview of the Company at the SVB Securities Global Biopharma Conference 2023, which is taking place in a virtual format.
-
Stereotaxis to Report Fourth Quarter and Full Year 2022 Financial Results on March 3, 2023
2/2/2023
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 fourth quarter and full year ended December 31, 2022 on Friday, March 3, 2023 before the open of the U.S. financial markets.
-
Integrated DNA Technologies Expands Access, Expedites Turnaround Time, for Minimal Residual Disease (MRD) Solutions for Cancer Research
2/1/2023
Integrated DNA Technologies Expands Access, Expedites Turnaround Time, for Minimal Residual Disease (MRD) Solutions for Cancer Research.